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Abstract 
 
The molecular complexity of triple-negative breast cancers (TNBCs) provides 
a challenge for patient management. We set out to characterise this 
heterogeneous disease by combining transcriptomics and genomics data, 
with the aim of revealing convergent pathway dependencies with potential for 
treatment intervention. A Bayesian algorithm was used to integrate molecular 
profiles in two TNBC cohorts, followed by validation using five independent 
cohorts (n = 1,168), including three clinical trials. A four-gene decision tree 
signature was identified which robustly classified TNBCs into six subtypes. All 
four genes in the signature (EXO1, TP53BP2, FOXM1 and RSU1) are 
associated with either genomic instability, malignant growth, or treatment 
response. One of the six subtypes, MC6, encompassed the largest proportion 
of tumours (~50%) in early diagnosed TNBCs. In TNBC patients with 
metastatic disease, the MC6 proportion was reduced to 25%, and was 
independently associated with a higher response rate to platinum-based 
chemotherapy. In TNBC cell line data, platinum-sensitivity was recapitulated, 
and a sensitivity to the inhibition of the phosphatase PPM1D was revealed. 
Molecularly, MC6-TNBCs displayed high levels of telomeric allelic 
imbalances, enrichment of CD4+ and CD8+ immune signatures, and genes 
negatively regulating the mitogen-activated protein kinase (MAPK) signalling 
pathway. These observations suggest that our integrative classification 
approach may identify TNBC patients with discernible and theoretically 
pharmacologically tractable features that merit further studies in prospective 
trials. 
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Introduction 
Triple-negative breast cancers (TNBCs), defined by the lack of oestrogen 
receptor (ER), progesterone receptor (PgR) and human epidermal growth 
factor receptor 2 (HER2) expression, display remarkable molecular complexity 
and heterogeneous clinical behaviour (1). The overall prognosis of women 
with TNBC after metastatic relapse is significantly poorer when compared to 
that of women with other breast cancer subtypes (2). Chemotherapy remains 
the only systemic therapeutic approach for TNBC patients. Although 
subpopulations can be identified that are more responsive to chemotherapy, 
such as those with BRCA1 mutations, its effectiveness remains limited in an 
unselected TNBC population. Many agents are presently in clinical 
development, including PARP inhibitors and platinum salts (3-5), MEK 
inhibitors (6), and immunological agents (7). For some, predictive biomarkers 
have been recognised, while for others appropriate molecular features 
enabling optimal patient selection are still lacking (8,9). 
Several studies have sought to take advantage of molecular profiling to 
classify TNBCs and subsequently provide clinically relevant information (10-
13). One of the most recent classifications, TNBCtype-4, is based on gene 
expression and classifies TNBC into four subtypes. Among those, basal-like 1 
(BL1) TNBCs were shown to achieve significantly higher pathological 
complete response (pCR) rates (49%) compared to all other subtypes (31%) 
when treated with neoadjuvant chemotherapy. However, classification 
approaches making use of multi-omics data are warranted to identify patients 
that may benefit from treatment beyond the standard-of-care (12). 
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TNBCs are characterised by extensive genomic instability (14,15). Measures 
capturing overall levels of genomic instability, like a chromosomal instability 
gene signature (CIN70), are informative for outcome prediction in ER-negative 
tumours (16). Similarly, genomic signatures, including Scars of Chromosomal 
Instability measures (SCINS) (17), Number of Telomeric Allelic Imbalance 
(NtAI) (18), the Homologous Recombination Deficiency (HRD) score (19), and 
HRDetect (20), are indicative of BRCAness and predictive of response to 
chemotherapy, particularly in the neoadjuvant setting (21). In metastatic 
TNBC trials (TNT (22) and TBCRC009 (23)), these methods were not able to 
identify patients specifically responding to platinum-based chemotherapy, 
suggesting some refinement of such approaches are required. 
Here, we developed a four-gene decision tree signature based on integrated 
transcriptomics and genomics data that robustly classifies TNBCs into 6 
subtypes across 1,168 TNBCs. In TNBC patients with metastatic disease, our 
classification identified a subgroup of tumours sensitive to platinum-based 
chemotherapy. Molecular characteristics of this subgroup included increased 
number of allelic imbalanced aberrations in their telomeres, decreased 
inactivation of MAPK signalling, and enrichment of CD4+ and CD8+ immune 
signatures. 
Materials and methods 
Clinical sample data 
TNBCs from the previously described Guy’s TNBC (E-MTAB-5270 and and E-
MTAB-2626) (24) were selected based on IHC status of HER2, ER and PgR. 
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For 88 TNBCs, patient matched Affymetrix GeneChip Human Exon 1.0ST 
gene expression and Affymetrix SNP 6.0 copy number data were available.  
METABRIC TNBC is a subset of the METABRIC study (EGAD00010000164) 
(10). Triple-negative status was based on IHC-assessed ER and HER2 
status. Patient matched Illumina Human HT-12 v3 gene expression and 
Affymetrix SNP 6.0 copy number data were available for 112 TNBCs and 
processed, as reported previously (24). 
A triple-negative subset of TCGA BRCA (25) was used as the TCGA TNBC 
cohort. For 95 TNBCs, defined by ER and HER2 status, gene expression was 
available on the Agilent 244K Custom Gene Expression array. 
The TNBC616 cohort is a compilation of 24 different breast cancer cohorts 
(Supplementary Table S1). A total of 3,495 breast cancers were obtained, of 
which 616 were defined as triple-negative based on HER2, ER and PgR 
status. Details are provided in the online Supplementary Information. 
Clinical trial data 
The PrECOG 0105 cohort comprised 80 patients enrolled in a single-arm, 
phase II, early-stage study assessing the efficacy of neoadjuvant treatment 
using gemcitabine and carboplatin plus iniparib (26) (NCT00813956) (5). 
Response to treatment was stratified using the residual cancer burden (RCB) 
index (27). Patients with RCB > 1 were considered treatment-unresponsive; 
those with an RCB of 0 were deemed to have pCR, while those with an RCB 
of 1 had a partial response. Affymetrix HuGene 1.0st microarray gene 
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expression was available and processed using the affy Bioconductor package 
(28) following RMA normalisation (29). 
Sanofi Phase II (NCT00540358) (3) and Sanofi Phase III (NCT00938652) (4) 
are both two-arm clinical trials in TNBC patients with metastatic disease 
testing the efficacy of gemcitabine and carboplatin, with or without iniparib. A 
total of 123 and 519 patients in Phase II and Phase III, respectively, were 
randomly assigned to either arm. From the 74 (Phase II) and 319 (Phase III) 
patients for which gene expression data from the primary lesions were 
obtained, objective response was available for 61 and 224 patients. Gene 
expression was available on the Affymetrix Human Genome U133 Plus 2.0 
microarray and was processed similarly to the PrECOG 0105 data. 
Affymetrix SNP 6.0 copy number data 
Raw Affymetrix SNP 6.0 data was normalised, allele-specific signal intensity 
measures were generated, and log R-ratio and B-allele frequencies were 
obtained using PennCNV-Affy (30,31). Allele specific copy number data was 
obtained using the ASCAT algorithm (32). 
Cancer cell lines data 
Transcriptomics and drug response data for TNBC cell lines (n = 16) was 
acquired from the Genomics of Drug Sensitivity in Cancer (GDSC) (33). The 
area under the dose response curve (AUC) values represent the relative 
sensitivity (low AUC) and resistance (high AUC) for each drug within each cell 
line. Associations between drug response and MC6 were assessed using 
Mann-Whitney U tests. 
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Statistical methods 
Detailed information on the integrative analysis and statistical methods are 
described in the online Supplementary Information. In brief, genomics and 
transcriptomics data was integrated independently in Guy’s TNBC and 
METABRIC TNBC using the COpy Number and EXpression In Cancer 
(CONEXIC) algorithm (34). The identified four-gene signature required for 
TNBC subtyping was normalised before applied to additional cohorts.  
Results 
Integrative analysis of transcriptomics and genomics data identifies a 
four-gene decision tree signature 
To determine if combined transcriptomics and genomics data could lead to a 
robust TNBC classification, we applied the previously published CONEXIC 
algorithm (34) to two independent TNBC cohorts; Guy’s TNBC (n = 88) (24) 
and TNBCs from the METABRIC study (METABRIC TNBC; n = 112) (10) 
(Figure 1A and Supplementary Table S1). CONEXIC constructs gene sets, 
defined as groups of genes which share similar expression patterns across all 
samples. As a next step, CONEXIC builds decision trees for each of these 
gene sets, using gene expression levels of copy number driven genes 
(modulators, copy number >=5). Within Guy’s TNBC and METABRIC TNBC, 
CONEXIC identified 38 and 36 gene sets with decision trees, respectively 
(Supplementary Table S2 and S3). We next sought to identify concurrent 
gene sets between the 38 Guy’s and 36 METABRIC gene sets by comparing 
all 1,368 possible gene set combinations for overlapping genes (Figure 1B) 
and identified 92 sets with statistically significant concurrent genes (Figure 
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1C, grey squares), including 3 gene sets that shared a common modulator in 
their respective decision trees, namely EXO1 (Figure 1C, black squares, and 
Figure 1D). In Guy’s-set 33 and METABRIC-set 15, genes involved in the 
inactivation of the mitogen-activated protein kinase (MAPK) pathway were 
significantly enriched (Supplementary Table S4). As no overlapping GO-terms 
were identified between Guy’s-set 27 and METABRIC-set 15, we focused on 
Guy’s-set 33 and METABRIC-set 15 (Supplementary Figure S1). 
A four-gene decision tree signature consistently classifies TNBCs into six 
subtypes in test cohorts.  
We applied both decision tree signatures to a total of 1,168 TNBCs, including 
(i) 95 TNBCs of TCGA BRCA (25); (ii) TNBC616 (see Supplementary Table 
S1 and online Supplementary Information); (iii) PrECOG 0105 (n = 64) (5), 
and both a phase II and a phase III trial in TNBC patients with metastatic 
disease; (iv) Sanofi Phase II (n = 74) (3) and (v) Sanofi Phase III (n = 319) (4) 
(Figure 1A). Transcriptomics data in each of the trials was derived from 
treatment naïve primary breast cancer tissue.  
The classification defined by the decision tree of Guy’s-set 33, which is based 
on the expression levels of five genes (ST8SIA1, EXO1, NEK2, C8orf46 and 
MMS22L), nominated TNBCs in some cohorts, such as TCGA BRCA and 
Sanofi III, mostly as one class (Supplementary Figure S2) and could not be 
tested in TNBC616 as expression levels for MMS22L and C8orf46 were not 
available for assessment. Further investigations based on the Guy’s-set 33 
decision tree were therefore not performed. In contrast, applying the 
METABRIC-set 15 decision tree signature based on the expression levels of 
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four genes (TP53BP2, EXO1, FOXM1 and RSU1), established six subtypes, 
named MC1 to MC6, including one large subtype and five of varying sizes 
(Figure 2). The most frequent subtype (MC6) comprised 44.6%, 47.7%, 
46.6% and 56.8% of all patients in METABRIC TNBC, Guy’s TNBC, 
TNBC616 and TCGA TNBC, respectively. In the PrECOG 0105 trial, the 
proportion of the MC6 subtype increased to 64%, whereas in TNBC patients 
with metastatic disease (Sanofi Phase II and III), its proportion reduced to 
~24%. In contrast, the frequency of MC1-TNBCs increased from ~7.2% in the 
non-trial cohorts to ~22.4% in the metastatic setting. No difference in overall 
survival or risk of developing metastasis was observed when the four genes 
were tested in a univariate or multivariate Cox survival analyses, neither do 
the different MC subtypes demonstrate any association with increased or 
decreased overall and progression free survival or risk of developing 
metastasis (Supplementary Table S5). 
Molecular characterisation of MC subtypes 
MC subtypes are non-synonymous with other breast cancer classifications. 
Currently, TNBCs are classified by TNBCtype-4 (12), the PAM50 subtypes 
(35-37) and the IntClust breast cancer classification (10). We sought to 
evaluate if the four-gene decision tree classification converges to these ones 
(Figure 3A and Supplementary Table S6 and S7). MC6-TNBCs consisted 
exclusively of PAM50 basal-like cases (100%, P = 2e-08, Fisher’s exact test), 
although only 57% of the basal-like TNBCs were classified as MC6. MC1-
TNBCs were enriched for Luminal A (36%, P = 3e-04, Fisher’s exact test) and 
Normal-Like (36%, P = 3e-03, Fisher’s exact test), and MC2-TNBCs for 
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HER2-enriched (57%, P = 2e-03, Fisher’s exact test). TNBCs of the remaining 
three MC subtypes fell across all PAM50 subtypes. Except for three TNBCs, 
MC6-TNBCs belonged to the IntClust 10 group (78%, P = 1e-02, Fisher’s 
exact test), whereas TNBCs of other MC subtypes were classified mostly as 
IntClust 4, 5, 3 and 1, although no significant enrichments were observed. 
MC6-TNBCs were found to be enriched for the BL1 subtype (61%, P = 1e-06, 
Fisher’s exact test), whereas MC1-TNBCs and MC2-TNBCs were primarily of 
the LAR subtype (86% and 67%, P = 1e-04 and 1e-02, respectively, Fisher’s 
exact test). Thus, the MC subtypes diverged from established breast cancer 
classifications 
MC subtypes differ in their immune gene enrichment. 
Based on Lehmann’s immunomodulatory (IM) classification (12), 37% of the 
MC6-TNBCs were IM-positive, MC1- and MC2-TNBCs were exclusively IM-
negative, and MC3-, MC4- and MC5-TNBCs were mostly IM-negative (74%) 
(Figure 3A). Next, we performed a gene set enrichment analysis (38) on gene 
expression data from METABRIC TNBC to further deconvolute immune cell 
enrichment across the MC subtype. Using 28 different immune gene sets 
(39), activated CD4+ and CD8+ immune signatures were found enriched in 
MC6-TNBCs (Q = 3e-08, and 1e-04, respectively, Mann-Whitney U test), and 
low in MC1-TNBCs (Q = 2e-05 and 1e-05, Mann-Whitney U test) (Figure 3A 
and Supplementary Table S8). MC6-TNBC had lower mastocytes and 
CD56dim natural killer cell activation in comparison to other MC subtypes (Q = 
5e-03, and 3e-02, respectively, Mann-Whitney U test). In MC3-TNBCs, 
increased central memory CD8+, effector memory CD8+ and immature 
dendritic cells expression levels were observed (Q = 4e-02, 4e-02 and 4e-02, 
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respectively, Mann-Whitney U test). MC2-TNBCs had reduced expression of 
the memory B cell signature (Q = 4e-02, Mann-Whitney U test), whereas in 
MC1-TNBCs, Th1 expression was reduced (Q = 4e-02, Mann-Whitney U 
test). This clearly demonstrates a variety of immune cell features across the 
MC subtypes. 
Pathway deregulation in MC subtypes. 
DUSP4, DUSP5, DUSP6, DUSP10 and SPRED2 were amongst the 
METABRIC-set 15 gene set (Figure 1D and Supplementary Table S2) and are 
involved in the negative regulation of the MAPK signalling pathway. We 
investigated their expression levels across the MC subtypes and found that 
MC6-TNBCs had the lowest expression of these genes in comparison to the 
other subtypes (P < 0.05, Mann-Whitney U test) (Figure 3B and 
Supplementary Figure S3A). Genomic regions encompassing DUSP4, 
DUSP5 and DUSP6 were deleted (Supplementary Table S9), potentially 
resulting in decreased expression levels. To further corroborate the lack of 
negative regulation of MAPK inactivation, a set of genes previously reported 
under control of this inhibitory mechanism (40) was interrogated in the MC 
subtypes and found increased in MC6-TNBCs compared to TNBCs of other 
MC subtypes (P < 0.05, Mann-Whitney U test) (Figure 3B and Supplementary 
Figure S3B). These results demonstrate the highly selective features of MC6-
TNBCs. 
In MC5-TNBCs, genes highly expressed were enriched for ErbB signalling (Q 
= 6e-03, Hypergeometric test), particularly through the epidermal growth 
factor receptor pathway (P = 1e-02, Fisher’s exact test). MC4-TNBCs were 
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enriched for PI3K/Akt signalling (Q = 5e-03, Hypergeometric test) and DNA 
replication (P = 2e-02, Fisher’s exact test). Although not enriched for 
Lehmann’s IM classification, many genes upregulated in MC3-TNBCs are 
involved in innate and adaptive immune response (P = 7e-04 and 1e-03, 
respectively, Fisher’s exact test), and chemokine signalling (Q = 3e-03, 
Hypergeometric test). MC2-TNBCs were enriched for metabolic processes (Q 
= 2e-28, Hypergeometric test), and MC1-TNBCs for steroid hormone 
mediated signalling (P = 3e-02, Fisher’s exact test), particularly oestrogen and 
androgen receptor signalling (P = 7e-04 and 2e-02, respectively, Fisher’s 
exact test). The unique pathway activities underlying the MC subtypes further 
demonstrate the molecular complexity of TNBC and further strengthen our 
TNBC classification. 
Increased levels of telomeric allelic imbalanced aberrations in MC6-TNBCs. 
Next, we investigated the levels of genomic instability. MC6-TNBCs showed 
significantly higher levels of chromosomal instability (P < 0.05, Mann-Whitney 
U test) (Figure 3C and Supplementary Figure S3C) as defined by the CIN70 
gene expression signature (16,41). MC1-TNBCs had the lowest levels of 
chromosomal instability. To further decipher this genomic instability, we 
investigated diverse genomic instability measurements based on copy 
number data (17,18). MC6-TNBCs displayed a high burden of allelic 
imbalanced aberrations in their telomeres (P = 9e-07, Mann-Whitney U test) 
(Figure 3C). MC5-TNBCs exhibited a medium burden. In contrast, the 
remaining MC subtypes did not harbour specific types of copy number 
aberrations. 
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MC6 identifies TNBCs responsive to platinum-based chemotherapy in Sanofi 
Phase III clinical trial.  
Given the selective features of MC6-TNBCs, we next assessed whether this 
subtype carried any predictive value in treatment response to DNA damaging 
agents. Using three clinical trials (Figure 1A), TNBCs from each cohort were 
dichotomised as either being MC6-TNBCs or non-MC6 (referred to as 
remaining TNBCs). We included the TNBCtype-4 classification as a 
comparator, as BL1-TNBCs were previously shown to be responsive to 
neoadjuvant chemotherapy (12). In the neoadjuvant PrECOG 0105 trial, the 
RCB 0/I pathological response rate in BL1-TNBCs (11/17, 65%) was similar to 
that of MC6-TNBCs (25/41, 61%) (Figure 4A). However, out of the 64 patients 
enrolled in the PrECOG 0105 trial, the MC6 subtype identified 39% of the 
responders with an accuracy of 55%, in contrast to the BL1 subtype, 
identifying 17%, with an accuracy of 41%. In the metastatic TNBC Sanofi 
Phase II trial, neither the BL1 nor the MC6 subtype was predictive of the 
overall response rate (ORR) (Figure 4B). However, in the metastatic TNBC 
Sanofi Phase III trial, the MC6 subtype was a significant predictor of treatment 
response in a multivariate model (OR = 2.41, CI = 1.01 to 5.81, P < 0.05), with 
an ORR in MC6-TNBCs of 46% (28/61), compared to an ORR of 30% 
(49/163) in the remaining TNBCs (Figure 4C). The ORR in BL1-TNBCs was 
41% (23/56), as compared with 32% (54/168) in the remaining TNBCs. In 
contrast to BL1, the MC6 subtype did reach significance in the univariate and 
in the multivariate model (OR = 1.78, CI = 0.76 to 4.19, P = 0.18) 
(Supplementary Table S10). 
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MC6 cell lines are sensitive to cisplatin.  
To test the hypothesis that MC6-TNBCs are responsive to platinum-based 
chemotherapeutics, we exploited drug sensitivity profiles of 16 TNBC tumour 
cell lines generated as part of the Genomics of Drug Sensitivity in Cancer 
(GDSC) project (33). We found that the median area under the curve (AUC) of 
cisplatin in the MC6 TNBC cell lines (n = 4) was 0.89, compared to 0.92 in cell 
lines from other MC subtypes (n = 11) (P = 5.6e-02, Mann-Whitney U test), 
suggesting an enhanced sensitivity to platinum salts in the MC6 subtype. With 
the aim of identifying novel alternative therapeutic sensitivities, we also 
assessed the associations between >200 GDSC drug response profiles and 
the MC6 subtype (Supplementary Table S11). We found that amongst the 
GDSC drug sensitivity profiles, MC6 TNBC cell lines displayed most 
sensitivity to CCT007093 (42), a small molecule inhibitor of the DNA-damage 
activated phosphatase, PPM1D (43) (P = 7.7e-03, Mann-Whitney U test, 
Supplementary Figure S4).  
Discussion 
With the purpose of classifying molecular heterogeneous TNBCs into clinically 
relevant subtypes, our multi-omics integrative approach differs from previously 
published methods (10-13). Our classification was constructed using data 
exclusively from TNBCs, strengthening the exploration of their molecular 
complexity in more detail. Robustness of our approach was increased by 
applying the CONEXIC algorithm (34) to two independent TNBC cohorts to 
then identify concurrent gene sets and modulatory genes. Guy’s-set 33 and 
METABRIC-set 15 shared similarities in both their gene set and modulatory 
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genes. The latter represented well known cancer-associated genes potentially 
contributing to tumour progression, and thereby substantiating our analytical 
approach to identify candidate drivers with effects on gene expression 
patterns. However, upon validation of both decision trees, only METABRIC-
set 15 was taken forward due to the consistently reproducible MC subtypes. 
Of note, the molecular features of primary tumours of patients that will be 
developing metastasis seem to be distinct, as was reflected by the change in 
proportion of the MC1 and MC6 subtype between non-trial genomic and 
metastatic TNBC cohorts. The MC6 subtype identified metastatic TNBC 
patients who showed improved response to platinum-based chemotherapy in 
the Sanofi Phase III, but not in the neoadjuvant PrECOG 0105 trial (5). In 
early stage TNBCs, which are more likely to respond to platinum-based 
chemotherapy, the MC6 subtype is not able to differentiate between those 
that do, and do not respond to this treatment. However, in the metastatic 
setting, where patients are less responsive to platinum-based chemotherapy, 
MC6 appears to be more discriminative as a predictor. In contrast, genomic 
signatures lack predictive value in the metastatic setting (22,23). 
The four-gene decision tree signature consists of TP53BP2, RSU1, FOXM1 
and EXO1. The expression of TP53BP2, a known regulator of apoptosis and 
cell growth, has been reported to be copy number dependent, and associated 
with poor response to chemotherapy in TNBC (14). RSU1, Ras suppressor-1, 
is involved in the RAS signal transduction pathway and was proposed as a 
biomarker for metastasis in breast cancers (44). The proto-oncogenic 
transcription factor FOXM1 has frequently been shown to mediate cell 
proliferation, survival, migration, progression and tumourigenesis in TNBC 
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(45); can modulate cisplatin sensitivity by regulating the expression of EXO1 
in ovarian cancer (46); and is part of a recently identified KRAS-associated 
signature in colorectal cancer (47). All four genes provide biological rationales 
for being good candidates for classification approaches. 
To further substantiate the finding that MC6-TNBCs were more sensitive to 
platinum-based chemotherapeutics, cisplatin drug response profiles were 
assessed across 16 TNBC cell lines categorised by MC subtypes. In line with 
findings from Sanofi Phase III, MC6 cell lines appeared overall more sensitive 
to cisplatin than those of other subtypes. In addition, MC6 TNBC cell lines 
were found to exhibit enhanced sensitivity to CCT007093, a chemical inhibitor 
of PPM1D (42). In parallel, MC6 TNBC cell lines displayed lower expression 
of DUSP10 and SPRED2 as a part of the MAPK inactivation signature; both 
are negative regulators of p38. Loss of DUSP4, DUSP5 and DUSP6 in TNBC 
has been previously reported by others (48-50). Thus, we hypothesise that 
the sensitivity to CCT007093 may be a result of p38-dependent cell death, 
thereby pointing to a potential PPM1D dependency for this group of TNBCs. 
Given that PPM1D modulates the activity of a series of substrates including 
p38, ATM, CHK1 and CHK2 (43), this association further demonstrates the 
connectivity between genomic instability and TNBC. 
The small number of genes in the proposed decision tree makes it an ideal 
classification approach to be performed with other platform methodologies, 
including qPCR, NanoString, with relative ease. However, there are some 
limitations as in its current form, the four-gene decision tree signature relies 
on the distribution of each of the four genes and careful standardisations 
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experiments would need be implemented. Further validation of our 
classification across independent clinical trials are warranted to investigate if 
association with treatment effect to platinum-based chemotherapy is specific 
or rather reflects a combinatorial effect with gemcitabine in Sanofi Phase III. 
The management of TNBC, especially in the metastatic setting, can be 
complex. With single-agent chemotherapy still considered the standard of 
care, targeted therapeutic strategies are required, which will rely on 
appropriate biomarkers for optimal patient selection. The unique molecular 
features of the MC subtypes reflect the intrinsic heterogeneity of TNBC and 
revealed targetable pathways, such as the p38 MAPK signalling pathway in 
MC6-TNBC. The same subset also showed elevated levels of genomic 
instability in telomeric regions, a type of genomic instability which may be the 
result of escaping from telomere crisis. EXO1, a modulatory gene, may further 
contribute to this process (51,52). Further characterisations of the MC 
subtypes are warranted to establish their association with genomic signatures 
from whole-genome sequence data (53,54). 
In conclusion, we sought to decipher the complex nature of TNBC, with the 
goal of informing patient selection for current and future treatment strategies. 
We showed that a four-gene decision tree signature based on copy number 
dependent genes classifies TNBCs into six subtypes. Given the current lack 
of selection criteria for TNBC patients with metastatic disease, this 
classification warrants further testing in randomised metastatic TNBC trials, 
such as TNT (22). 
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Figure Legends 
Figure 1. Identification of concurrent cancer gene sets with CONEXIC. (A) 
Research design and workflow. After selecting a decision tree, a molecular 
characterisation of the subtypes was performed in two discovery and five 
validation sets. Treatment response to DNA damaging agents was assessed 
in three clinical trials. (B) The number of gene sets, decision trees and 
modulators identified by the CONEXIC algorithm in Guy’s TNBC and 
METABRIC TNBC. Overlap in gene set composition between the two cohorts 
was assessed using a one-sided Fisher’s exact test. (C) Level plot of 
concurrent gene sets between the Guy’s TNBC and METABRIC TNBC 
cohorts. Dark grey boxes indicate gene sets with significantly overlapping 
genes. Black boxes, as dark grey boxes, in addition to overlapping 
modulators. Gene sets are ordered by size. (D) Venn diagram depicting the 
number of common genes between Guy’s-set 27, Guy’s-set 33, and 
METABRIC-set 15.  
Figure 2. TNBC cohorts classified using the METABRIC-set 15 four-gene 
decision tree signature. Pie charts illustrating the proportion of the MC 
subtypes in four primary invasive TNBC cohorts, namely METABRIC TNBC, 
Guy’s TNBC, TNBC616 and TCGA TNBC, as well as three clinical TNBC 
studies, including PrECOG 0105, Sanofi Phase II and Sanofi Phase III. The 
total number of tumours in each cohort is listed in brackets. The percentage 
for each subgroup is shown outside the respective pies.  
Figure 3. Molecular characterisation of the MC subtypes in METABRIC 
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TNBC. (A) The four-gene decision tree underlying the MC subtypes is shown, 
followed by a heat map representing the expression levels of the four 
modulatory genes. Sample-specific characteristics include PAM50, IntClust, 
TNBCtype-4 and the CIN70 signature. Level plot illustrates the enrichment of 
immune gene signatures. (B) (left) The MAPK inactivation scores, calculated 
by summarising the expression levels of DUSP4, DUSP5, DUSP6, DUSP10 
and SPRED2, was compared between MC6-TNBCs (magenta) and the 
remaining TNBCs (grey). Significance was assessed using Wilcoxon rank-
sum tests. (right) The z-scores for the DUSP6 gene set were obtained using 
ssGSEA. Significance was assessed using a Wilcoxon rank-sum test. (C) 
Boxplots displaying the CIN70 signature (left) and NtAI (right) in MC6-TNBCs 
(magenta) and the remaining TNBCs (grey). Significance was assessed using 
Wilcoxon rank-sum tests.  
Figure 4. Response rates for the MC6 and BL1 subtypes in clinical trials. (A) 
Response to neoadjuvant platinum-based chemotherapy, as assessed by the 
RCB index, in BL1-TNBCs and MC6-TNBCs obtained from the PrECOG 0105 
clinical trial. (B) ORR in Sanofi Phase II and (C) Sanofi Phase III. Response 
rates are dichotomised by being BL1 or not (left), and MC6 or not (right). 
Subtypes were assessed as predictors of treatment response using a 
multivariate logistic regression, by including age and race for Sanofi II, and 
age, race, and grade for Sanofi III into the models. 
  
Integrative analysis of triple-negative breast cancers  27 
Supplementary Figures and Tables 
Supplementary Figure S1. Boxplots depicting the association between gene 
expression levels (y-axis) and copy number status (x-axis) for each of the 
modulatory genes in (A) Guy’s-set 33 and (B) METABRIC-set 15. Tumours 
are grouped based on their copy number status with loss (copy number = 1), 
normal (copy number = 2) or gain (copy number >= 5). Significance was 
assessed using a Kruskal-Wallis test.  
Supplementary Figure S2. Classification of TNBC cohorts using the Guy’s-
set 33 decision tree. The pie charts illustrate the proportion of the GC 
subtypes in four primary invasive TNBC cohorts (METABRIC TNBC, Guy’s 
TNBC, TNBC616 and TCGA TNBC), as well as in three clinical TNBC studies 
(PrECOG 0105, Sanofi Phase II, Sanofi Phase III). The number of tumours is 
listed in brackets and the percentage for each subtype is shown outside its 
respective pie.  
Supplementary Figure S3. Molecular characterisation of the MC6 subtype in 
the six TNBC cohorts. Boxplots representing (A) the MAPK inactivation score, 
(B) the enrichment gene set of the Furukawa et al. 2006 (40), and (C) the 
CIN70 gene signature between MC6-TNBCs (magenta) and non-MC6-TNBCs 
(rest; grey). Significance was assessed using Wilcoxon rank-sum tests. 
Supplementary Figure S4. Barplot representing sensitivity to CCT007093, a 
small molecule PPM1D inhibitor, in TNBC cell line models (x-axis). The AUC 
(y-axis) represents the relative drug sensitivity, whereby a lower AUC 
indicates an increased sensitivity. Cell line models are ranked according to 
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their AUC and bars are coloured by MC classification. 
Supplementary Table S1. Overview of all cohorts, including the number of 
TNBCs, doi numbers and accessions. A separate table providing an overview 
of the 24 different data sources included in the TNBC616 is included. 
Supplementary Table S2. List of gene sets identified by CONEXIC in Guy’s 
TNBC and METABRIC TNBC. Each row represents a gene set with its 
members listed as Entrez gene identifiers. Gene sets, for which a decision 
tree were constructed by CONEXIC, were annotated accordingly in the 
Decision Tree column. 
Supplementary Table S3. Table of modulatory genes identified by CONEXIC 
in Guy’s TNBC and METABRIC TNBC. Modulators are annotated by HGNC 
symbol, Entrez gene identifiers, chromosome, and start and stop position. 
Supplementary Table S4. List of significantly enriched GO biological 
processes in Guy’s-set 27, Guy’s-set 33 and METABRIC-set 15. For each GO 
biological process, the number genes part of the processes and present on 
the microarray is reported (Annotated), followed by the number of genes 
present in the gene set. A Fisher’s exact test is used to determine the 
significance (classic Fisher’s exact test). 
Supplementary Table S5. Survival analysis in Guy’s TNBC, METABRIC 
TNBC, Sanofi Phase II and Sanofi Phase III using both the individual and the 
MC subtypes. For the individual genes, patients are stratified either by median 
gene expression or into tertiles. The MC1, MC2 and MC3 subtypes were 
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excluded from the analysis in Guy’s TNBC cohort due to the limited (less than 
3) number of patients. 
Supplementary Table S6. Concordance between the METABRIC-set 15 (MC 
subtypes) classification and intrinsic breast cancer subtypes, including 
PAM50, IntClust, and TNBCtype-4, in the METABRIC TNBC cohort. Fisher’s 
exact tests were utilised to assess the significance, whereby significant results 
are annotated in red. 
Supplementary Table S7. Clinicopathological features of the METABRIC-set 
15 (MC subtypes) classification in the METABRIC TNBC cohort. 
Supplementary Table S8. Results from the gene set enrichment analysis of 
28 different immune signatures across the METABRIC-set 15 (MC subtypes) 
classification. Z-score transformed normalised enrichment scores were 
obtained from ssGSEA. Significance was assessed using Mann–Whitney U 
tests, with significant results annotated in red. 
Supplementary Table S9. Table representing the copy number status of the 
five genes part of the MAPK inactivation score across the METABRIC-set 15 
(MC subtypes) classification. Copy number status is grouped by loss (copy 
number <2), normal (copy number = 2), gain (copy number = 3 or 4) or 
amplification (copy number >= 5). 
Supplementary Table S10. Output of the multivariable logistic regression 
analysis for the MC6 and the BL1 subtype in Sanofi Phase II and Sanofi 
Phase III. 
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Supplementary Table S11. Results from the drug screen performed between 
MC6 and non-MC6 TNBC cell lines. A total of 217 drugs were screed across 
16 TNBC cell lines from GDSC, including BT20, BT549, CAL120, CAL51, 
CAL851, HCC1143, HCC1187, HCC1395, HCC1937, HCC38, HCC70, 
HDQP1, HS578T, MDAMB157, MDAMB231, MDAMB436. For each drug, 
AUC values were compared between MC6 and non-MC6 TNBC cell lines. 
Significant results are annotated in red. 




